(S)-Opnurasib
Based on 1 Customer Validation
(S)-Opnurasib ((S)-JDQ-443; (S)-NVP-JDQ443) is an isomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.11%
- CAS 番号: 2653994-10-4
- 分子式: C29H28ClN7O
- 分子量:526.03
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1437 | GI50 |
4.4 μM
Compound: 21; JDQ443
|
Antiproliferative activity against human NCI-H1437 cells by resazurin assay
Antiproliferative activity against human NCI-H1437 cells by resazurin assay
|
[PMID: 36399068] |
| NCI-H358 | GI50 |
0.018 μM
Compound: 21; JDQ443
|
Antiproliferative activity against human NCI-H358 cells by resazurin assay
Antiproliferative activity against human NCI-H358 cells by resazurin assay
|
[PMID: 36399068] |
体外実験
Opnurasib traps the GDP-bound inactive conformation of KRAS[1].
Opnurasib promotes dose-dependent reductions of phosphorylated ERK (pERK) levels and the proliferation of the KRASG12C-mutated cell lines NCI-H358 and NCI-H2122, with IC50 values of 0.018 and 0.063 μM, respectively[2].
Opnurasib covalently and selectively binds and inhibits GDP-bound KRASG12C with low reversible binding affinity to the RAS switch II pocket, and also inhibits proliferation of KRASG12C-mutated and KRAS G12C/H95, G12C/R68S, and G12C/Y96 double-mutant cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Opnurasib (Orally, 100 mg/kg, daily (JDQ443) + 7.5 mg/kg, twice daily (TNO155), for 36 days) shows greater cell growth inhibition or cell killing compared with single-agent JDQ443 when combined with TNO155[2].
Opnurasib generates categorical antitumor responses in PDX models of NSCLC and colorectal tumors that are improved by combination treatment with other agents[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2653994-10-4
-
性状 Solid
-
分子量 526.03
-
分子式 C29H28ClN7O
-
Color Off-white to light yellow
-
SMILES
O=C(C=C)N1CC2(C1)CC(N3N=C(C4=CC=C5C(C=NN5C)=C4)[C@@]([C@@]6=C(Cl)C(C)=CC7=C6C=NN7)=C3C)C2
-
別名
(S)-JDQ-443; (S)-NVP-JDQ443
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (190.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.
[2]. Weiss A, Lorthiois E, Barys L, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022;candisc.0158.2022. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9010 mL | 9.5052 mL | 19.0103 mL | 47.5258 mL |
| 5 mM | 0.3802 mL | 1.9010 mL | 3.8021 mL | 9.5052 mL | |
| 10 mM | 0.1901 mL | 0.9505 mL | 1.9010 mL | 4.7526 mL | |
| 15 mM | 0.1267 mL | 0.6337 mL | 1.2674 mL | 3.1684 mL | |
| 20 mM | 0.0951 mL | 0.4753 mL | 0.9505 mL | 2.3763 mL | |
| 25 mM | 0.0760 mL | 0.3802 mL | 0.7604 mL | 1.9010 mL | |
| 30 mM | 0.0634 mL | 0.3168 mL | 0.6337 mL | 1.5842 mL | |
| 40 mM | 0.0475 mL | 0.2376 mL | 0.4753 mL | 1.1881 mL | |
| 50 mM | 0.0380 mL | 0.1901 mL | 0.3802 mL | 0.9505 mL | |
| 60 mM | 0.0317 mL | 0.1584 mL | 0.3168 mL | 0.7921 mL | |
| 80 mM | 0.0238 mL | 0.1188 mL | 0.2376 mL | 0.5941 mL | |
| 100 mM | 0.0190 mL | 0.0951 mL | 0.1901 mL | 0.4753 mL |
(S)-Opnurasib 関連分類
HY-139612A 関連分類
Powered by Bioz